The injection therapy denecimig for hemophilia A — designed to prevent bleeding episodes in adults and children with or…
Marisa Horak, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Horak, MS
The U.S. Food and Drug Administration (FDA) has given the go-ahead for Metagenomi Therapeutics to start a first-in-human clinical…
Note: This story was updated Nov. 12, 2026, to clarify that the art, IV Couture, was created with unused supplies;…
By educating and empowering patients and their families, clinicians can help improve access to accurate diagnoses and care for women…
Treatment disruptions during the height of the COVID-19 pandemic were a substantial driver of psychological distress for people with…
Hemophilia A patients rack up high hospital bills, driving costs for the healthcare system higher, a study from Canada…
A branch of the European Medicines Agency (EMA) has recommended that the experimental therapy denecimig be approved to treat…
In children with severe hemophilia A who are undergoing treatment to remove inhibitors, adding Hemlibra (emicizumab-KXWH) was associated…
Alvotech and Lotus Pharmaceutical are teaming up on plans to commercialize AVT87, a proposed biosimilar to Hemlibra…
Upfront treatment with Hemlibra (emicizumab-KXWH) may help reduce hospitalization costs associated with treating bleeds in older adults with…